

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 39/385</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/05900</b> <b>(43) International Publication Date:</b> 20 February 1997 (20.02.97)
<b>(21) International Application Number:</b> PCT/NL96/00317 <b>(22) International Filing Date:</b> 5 August 1996 (05.08.96) <b>(30) Priority Data:</b> 95202123.6 3 August 1995 (03.08.95) EP <b>(34) Countries for which the regional or international application was filed:</b> AT et al.  <b>(71) Applicants (for all designated States except US):</b> RIJKSUNIVERSITEIT TE LEIDEN [NL/NL]; Stationsweg 46, NL-2312 AV Leiden (NL). RIJKSUNIVERSITEIT UTRECHT [NL/NL]; Universiteitsweg 100, NL-3584 CG Utrecht (NL).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> GEUZE, Johannes, J. [NL/NL]; Rijksuniversiteit Utrecht, Universiteitsweg 100, NL-3584 CG Utrecht (NL). MELIEF, Cornelis, J., M. [NL/NL]; Rijksuniversiteit te Leiden, Stationsweg 46, NL-2312 AV Leiden (NL).  <b>(74) Agent:</b> SMULDERS, Th., A., H., J.; Vereenigde Octrooibureaux, Nieuwe Parklaan 97, NL-2587 BN The Hague (NL).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> CELL DERIVED ANTIGEN PRESENTING VESICLES  <b>(57) Abstract</b>  The invention provides a novel vehicle for vaccination, in particular peptide vaccination. The new vehicle has been termed an exosome. Exosomes are vesicles derived from MHC class II enriched compartments in antigen presenting cells. The exosomes possess MHC II and/or MHC I molecules at their surface and possibly peptides derived from processed antigens in said MHC's. Thus the exosome is a perfect vaccination vehicle in that it presents the peptide in a natural setting. The peptides present in the exosome in the MHC molecule may be processed by the antigen presenting cell from which the exosome is derived. Empty MHC molecules on exosomes may also be loaded with peptides afterwards.		